X
2.06
-0.13 (-5.72%)
| 前收盘价格 | 2.19 |
| 收盘价格 | 2.16 |
| 成交量 | 6,780,512 |
| 平均成交量 (3个月) | 2,953,788 |
| 市值 | 251,746,416 |
| 价格/销量 (P/S) | 1.73 |
| 股市价格/股市净资产 (P/B) | 5.17 |
| 52周波幅 | |
| 利润日期 | 2 Aug 2023 - 7 Aug 2023 |
| 营业毛利率 | 46.54% |
| 营业利益率 (TTM) | -32.78% |
| 稀释每股收益 (EPS TTM) | 2.11 |
| 总债务/股东权益 (D/E MRQ) | 340.14% |
| 流动比率 (MRQ) | 3.70 |
| 营业现金流 (OCF TTM) | -109.67 M |
| 杠杆自由现金流 (LFCF TTM) | -78.01 M |
| 资产报酬率 (ROA TTM) | -58.61% |
| 股东权益报酬率 (ROE TTM) | 121.75% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | X4 Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -1.5 |
| 平均 | 0.63 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.43% |
| 机构持股比例 | 55.70% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 10.00 (Stifel, 385.44%) | 购买 |
| 中 | 7.50 (264.08%) | |
| 低 | 5.00 (HC Wainwright & Co., 142.72%) | 购买 |
| 平均值 | 7.50 (264.08%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 3.72 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 05 Dec 2025 | 10.00 (385.44%) | 购买 | 3.80 |
| HC Wainwright & Co. | 10 Nov 2025 | 5.00 (142.72%) | 购买 | 3.63 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合